Silence Therapeutics plc filed a Current Report on Form 8-K on November 12, 2026, furnishing a press release with its financial and business results for the third quarter ended September 30, 2026, alongside an update on a definitive acquisition agreement with Merck KGaA, Darmstadt, Germany.
Key Highlights
- Acquisition agreement: On October 19, 2026, Silence announced a definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany, with the transaction expected to close in the first quarter of 2027, subject to customary closing conditions.
- Cash position: Cash and cash equivalents were $247.7 million as of September 30, 2026, including $201.3 million in gross proceeds from an upsized public offering announced August 11, 2026.
- Net loss: Net loss was $12.4 million, or $0.08 basic and diluted net loss per share, for the three months ended September 30, 2026, compared to a net loss of $21.0 million, or $0.15 per share, for the same period in 2025.
- R&D expenses: Research and development expenses were $9.3 million for Q3 2026, down from $20.5 million for Q3 2025, a decrease of $11.2 million attributed mainly to zerlasiran Phase 3 readiness being completed in 2025 and reduced personnel costs.
- G&A expenses: General and administrative expenses were $4.9 million for Q3 2026, compared to $5.8 million for Q3 2025, a decrease of $0.9 million attributed to efforts to reduce administrative costs.
- Shares outstanding: Total outstanding shares were 186,609,073 ordinary shares (including shares in the form of American Depositary Shares) as of September 30, 2026.
- Divesiran Phase 2 results: On August 10, 2026, Silence reported positive topline results from its Phase 2 SANRECO trial of divesiran in polycythemia vera, with results accepted for oral presentation at the ASH 2026 Annual Meeting, December 12-15, 2026, in New Orleans, LA.
Silence Therapeutics Q3 2026 Financials and Pending Acquisition by Merck KGaA
According to the filing, Silence Therapeutics plc (NASDAQ:SLN) reported its third quarter 2026 financial results while disclosing a definitive agreement, announced October 19, 2026, to be acquired by Merck KGaA, Darmstadt, Germany. The company disclosed that the transaction is expected to close in the first quarter of 2027, subject to the satisfaction of customary closing conditions. The filing noted that Silence intends to file a proxy statement with the SEC in connection with the proposed transaction.
On the financial side, the company reported a net loss of $12.4 million for the three months ended September 30, 2026, compared to a net loss of $21.0 million for the same period a year earlier. The filing attributed the year-over-year improvement primarily to lower R&D spending, as zerlasiran Phase 3 readiness activities were completed in 2025, combined with reduced personnel costs and administrative cost reduction efforts. Cash and cash equivalents stood at $247.7 million as of September 30, 2026, bolstered by $201.3 million in gross proceeds from an upsized public offering announced August 11, 2026.
On the clinical side, the company disclosed positive topline results from the Phase 2 SANRECO trial of divesiran, described in the filing as "an investigational siRNA therapy silencing TMPRSS6," in polycythemia vera, "supporting a potentially best-in-class profile with once-every-three-month dosing." The filing also noted that the SANRECO Phase 2 results have been accepted for oral presentation at the ASH 2026 Annual Meeting. The 8-K was signed by Iain Ross, Interim Principal Executive Officer and Chairman of the Board of Directors.
What Was Disclosed
Silence Therapeutics furnished its Q3 2026 financial results and business update via a press release attached to a Form 8-K filed November 12, 2026, covering the quarter ended September 30, 2026, and disclosing a pending acquisition by Merck KGaA, Darmstadt, Germany.



Please wait processing your request...